This startup wants to destroy cancer tumors using ultrasound instead of surgery

HistoSonics uses focused ultrasound pulses to non-invasively destroy tumor cells without harming healthy tissue. FDA-approved in 2023, the $2.25B company has treated ~4,000 patients, with trials expanding to kidney, prostate, and pancreatic cancers.